La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Actinium Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Actinium Pharmaceuticals' est Sandesh Seth, nommé en Jun2017, a un mandat de 7.17 ans. La rémunération annuelle totale est $ 4.71M, composée du salaire de 15% et des bonus 85%, y compris les actions et options de la société. détient directement 0.017% des actions de la société, d'une valeur de $ 11.24K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.9 ans et 10.8 ans.

Informations clés

Sandesh Seth

Directeur général

US$4.7m

Rémunération totale

Pourcentage du salaire du PDG	15.0%
Durée du mandat du directeur général	7.3yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	3yrs
Durée moyenne du mandat des membres du conseil d'administration	10.8yrs

Mises à jour récentes de la gestion

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Analyse de la rémunération des PDG

Comment la rémunération de Sandesh Seth a-t-elle évolué par rapport aux bénéfices de Actinium Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$43m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$5m	US$705k	-US$49m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$4m	US$665k	-US$33m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$2m	US$615k	-US$25m
Sep 30 2021	n/a	n/a	-US$23m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$2m	US$578k	-US$22m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$1m	US$561k	-US$22m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$545k	-US$24m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$25m
Dec 31 2017	US$306k	US$306k	-US$27m

Rémunération vs marché: La rémunération totale de Sandesh ($USD 4.71M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Sandesh a augmenté alors que l'entreprise n'est pas rentable.

PDG

Sandesh Seth (60 yo)

7.3yrs

Titularisation

US$4,705,000

Compensation

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK)...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Sandesh Seth	Chairman & CEO	7.3yrs	US$4.71m	0.017% $ 9.7k
Steven O'Loughlin	CFO & Corporate Secretary	7.3yrs	US$1.49m	0.0038% $ 2.1k
Paul Diamond	Vice President of Patent & Legal Counsel	3yrs	pas de données	pas de données
Avinash Desai	Chief Medical Officer	3.8yrs	pas de données	pas de données
Jenny Hsieh	Chief Strategy Officer	1.9yrs	pas de données	pas de données
Sunitha Lakshminarayanan	Senior VP	1.9yrs	pas de données	pas de données
Caroline Yarbrough	Chief Commercial Officer	1.8yrs	pas de données	pas de données
Lynn Bodarky	Chief Business Officer	less than a year	pas de données	pas de données
J. Simeon	Executive Director of Quality Assurance	8yrs	pas de données	pas de données
Madhuri Vusirikala	Vice President of Clinical Development BMT & Cellular Therapy	no data	pas de données	pas de données

3.0yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ATNM est considérée comme expérimentée (ancienneté moyenne 2.9 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sandesh Seth	Chairman & CEO	12.5yrs	US$4.71m	0.017% $ 9.7k
Richard Steinhart	Independent Director	10.8yrs	US$313.00k	0.0010% $ 566.4
David Scheinberg	Member of Clinical Advisory Board	no data	pas de données	pas de données
Hagop M. Kantarjian	Member of Clinical Advisory Board	no data	pas de données	pas de données
Richard Wahl	Member of Clinical Advisory Board	no data	pas de données	pas de données
Ajit S. Shetty	Independent Director	7.5yrs	US$308.50k	0.0024% $ 1.4k
C. Nicholson	Lead Independent Director	16.7yrs	US$313.00k	0.0011% $ 600.0
Joseph Jurcic	Chairman of Clinical Advisory Board	no data	pas de données	pas de données
Elihu Estey	Member of Clinical Advisory Board	no data	pas de données	pas de données
John Pagel	Chairman of Scientific Advisory Board & Member of Clinical Advisory Board	no data	pas de données	pas de données
Alexander Perl	Member of Clinical Advisory Board	no data	pas de données	pas de données
Sergio Giralt	Member of Scientific Advisory Board	10.3yrs	pas de données	pas de données

10.8yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration ATNM sont chevronnés et expérimentés (durée moyenne d'administration 10.8 ans).

Actinium Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Insufficient new directors

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Recent updates

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Consensus forecasts updated

Price target decreased to US$35.00

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

New 90-day low: US$7.75

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA Trial

New 90-day low: US$8.08